Current press information on migraine and headache research, migraine and headache diagnostics, migraine and headache therapy
Application for approval of Emgality® for the prophylaxis of episodic cluster headaches rejected
On Friday, February 27, 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced on its website that it recommends that the marketing authorization application for Emgality® (galcanezumab) for the prophylaxis of episodic cluster headache in adults [.. .]